D-068

Duloxetine-D₃ 塩酸塩 溶液

100 μg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant^®

• 実験式（ヒル表記法）: C₁₈D₃H₁₆NOS · HCl
• 分子量: 336.89
• EC Number: 200-659-6
• MDL番号: MFCD09752117
• UNSPSCコード: 41116107
• PubChem Substance ID: 329798627
• NACRES: NA.24

特性

• グレード: certified reference material
• 品質水準: 300
• 形状: liquid
• 特徴: Snap-N-Spike^®/Snap-N-Shoot^®
• 包装: ampule of 1 mL
• メーカー／製品名: Cerilliant^®
• 濃度: 100 μg/mL in methanol (as free base)
• テクニック: gas chromatography (GC): suitable; liquid chromatography (LC): suitable
• アプリケーション: clinical testing
• フォーマット: single component solution
• 保管温度: −20°C
• SMILES記法: Cl.[2H]C([2H])([2H])NCC[C@H](Oc1cccc2ccccc12)c3cccs3
• InChI: 1S/C18H19NOS.ClH/c1-19-12-11-17(18-10-5-13-21-18)20-16-9-4-7-14-6-2-3-8-15(14)16;/h2-10,13,17,19H,11-12H2,1H3;1H/t17-;/m0./s1/i1D3;
• InChI Key: BFFSMCNJSOPUAY-HQKLNPQUSA-N

詳細

詳細

臨床中毒学および尿中薬物試験における法医学的分析および同位体希釈法のための多くの GC/MS および LC/MS アプリケーションに適した安定同位体標識内部標準物質です。米国では Cymbalta^® の商標で市販されている Duloxetine は、セロトニン‐ノルエピネフリン再吸収阻害剤（SNRI）で、大うつ病性障害の治療および、糖尿病性神経障害、線維筋痛および変形性関節症に伴う痛みの緩和に用いられます。

アプリケーション

• Rapid Structure-Based Screening for COVID-19: Duloxetine-D₃ hydrochloride solution plays a key role in rapid structure-based screening, potentially informing the development of therapeutic agents for COVID-19 due to its properties as a serotonin-norepinephrine reuptake inhibitor, crucial for high-impact pharmaceutical research (Yang et al., 2020).


• UV-Triggered Drug Release: The high-purity Duloxetine-D₃ solution enhances UV-triggered drug release studies from mesoporous titanium nanoparticles loaded with pharmaceutical agents, indicating significant benefits for developing controlled drug delivery systems in biotechnological applications (Zuo et al., 2024).


• Antioxidant Activity and Eczema Treatment: Duloxetine-D₃ HCl serves as an internal standard in studies evaluating the antioxidant activities and therapeutic applications of drug-loaded liposomes for eczema treatment, highlighting its role in enhancing bioanalytical assay development (Shen et al., 2024).


• Synthesis and Application of EGFR Inhibitors for Cancer: As a stable isotope-labeled compound, Duloxetine-D₃ hydrochloride is used in the synthesis and clinical application studies of small-molecule EGFR inhibitors, underlining its critical application in cancer therapy research (Wang et al., 2024).


• Nanoparticle Drug Release Behaviors: The solution′s role in studying poly(lactic-co-glycolic acid) nanoparticles highlights its utility in pharmaceutical-grade calibration for analyzing hydrophilic and hydrophobic drug release behaviors, essential for pharmaceutical and biomedical research (Wang et al., 2024).

法的情報

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany

Cymbalta is a registered trademark of Eli Lilly and Co.

Snap-N-Shoot is a registered trademark of Cerilliant Corporation

Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

安全性情報

• ピクトグラム: GHS02,GHS06,GHS08
• シグナルワード: Danger
• 危険有害性情報: H225,H301 + H311 + H331,H370
• 注意書き: P210 - P280 - P301 + P310 + P330 - P302 + P352 + P312 - P304 + P340 + P311
• 危険有害性の分類: Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1
• ターゲットの組織: Eyes
• 保管分類コード: 3 - Flammable liquids
• WGK: WGK 1
• 引火点(°F): 49.5 °F - closed cup
• 引火点(℃): 9.7 °C - closed cup